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Introduction: The existence of cancer stem cells (CSCs) has been associated with tumor initiation, therapy
resistance, tumor relapse, angiogenesis, and metastasis. Curcumin, a plant ployphenol, has several anti-tumor effects
and has been shown to target CSCs. Here, we aimed at evaluating (i) the mechanisms underlying the aggravated
migration potential of breast CSCs (bCSCs) and (ii) the effects of curcumin in modulating the same.
Methods: The migratory behavior of MCF-7 bCSCs was assessed by using cell adhesion, spreading, transwell
migration, and three-dimensional invasion assays. Stem cell characteristics were studied by using flow cytometry.
The effects of curcumin on bCSCs were deciphered by cell viability assay, Western blotting, confocal microscopy,
and small interfering RNA (siRNA)-mediated gene silencing. Evaluations of samples of patients with breast cancer
were performed by using immunohistochemistry and flow cytometry.
Results: Here, we report that bCSCs are endowed with aggravated migration property due to the inherent
suppression of the tumor suppressor, E-cadherin, which is restored by curcumin. A search for the underlying
mechanism revealed that, in bCSCs, higher nuclear translocation of beta-catenin (i) decreases E-cadherin/beta-catenin
complex formation and membrane retention of beta-catenin, (ii) upregulates the expression of its epithelial-mesenchymal
transition (EMT)-promoting target genes (including Slug), and thereby (iii) downregulates E-cadherin transcription to
subsequently promote EMT and migration of these bCSCs. In contrast, curcumin inhibits beta-catenin nuclear
translocation, thus impeding trans-activation of Slug. As a consequence, E-cadherin expression is restored, thereby
increasing E-cadherin/beta-catenin complex formation and cytosolic retention of more beta-catenin to finally suppress
EMT and migration of bCSCs.
Conclusions: Cumulatively, our findings disclose that curcumin inhibits bCSC migration by amplifying E-cadherin/
beta-catenin negative feedback loop.Introduction
Breast cancer is the most common form of cancer diag-
nosed in women. In 2013, breast cancer accounted for
29% of all new cancer cases and 14% of all cancer deaths
among women worldwide [1]. Breast cancer-related mor-
tality is associated with the development of metastatic po-
tential of the primary tumor [2]. Given this high rate of
incidence and mortality, it is critical to understand the
mechanisms behind metastasis and identify new targets* Correspondence: tanya@jcbose.ac.in
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article, unless otherwise stated.for therapy. For the last few decades, various modalities of
cancer therapy were being investigated. But the disease
has remained unconquered, largely because of its invasive
nature.
Amidst the research efforts to better understand cancer
progression, there has been increasing evidence that hints
at a role for a subpopulation of tumorigenic cancer cells,
termed cancer stem cells (CSCs), in metastasis formation
[3]. CSCs are characterized by their preferential ability
to initiate and propagate tumor growth and their select-
ive capacity for self-renewal and differentiation into less
tumorigenic cancer cells [4]. There are reports which
demonstrate that CSCs are enriched among circulatingtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cancer [5]. Moreover, recent studies show that epithelial-
mesenchymal transition (EMT), an early step of tumor cell
migration, can induce differentiated cancer cells into a
CSC-like state [6]. These observations have established a
functional link between CSCs and EMT and suggest that
CSCs may underlie local and distant metastases by acquir-
ing mesenchymal features which would greatly facilitate
systemic dissemination from the primary tumor mass [7].
Taken together, these studies suggest that CSCs may be a
critical factor in the metastatic cascade. Now, the incur-
ability of the malignancy of the disease raises the question
of whether conventional anti-cancer therapies target the
correct cells since the actual culprits appear to be evasive
of current treatment modalities.
Studies focusing on the early steps in the metastatic cas-
cade, such as EMT and altered cell adhesion and motility,
have demonstrated that aggressive cancer progression is
correlated with the loss of epithelial characteristics and
the gain of migratory and mesenchymal phenotype [8],
for which downregulation of E-cadherin is a fundamental
event [9]. A transcriptional consequence of the presence
of E-cadherin in epithelial cells can be inferred from the
normal association of E-cadherin with β-catenin in adhe-
rens junctions. This association prevents β-catenin trans-
fer to the nucleus and impedes its role as a transcriptional
activator, which occurs through its interaction mainly with
the TCF (T-cell factor)-LEF (lymphoid enhancer factor)
family of transcription factors but also with other DNA-
binding proteins [10]. Accordingly, the involvement of β-
catenin signaling in EMTs during tumor invasion has been
established [11]. Aberrant expression of β-catenin has
been reported to induce malignant pathways in normal
cells [12]. In fact, β-catenin acts as an oncogene and
modulates transcription of genes to drive cancer initiation,
progression, survival, and relapse [12]. All of the existing
information regarding abnormal expression and function
of β-catenin in cancer makes it a putative drug target [12]
since its targeting will negatively affect both tumor metas-
tasis and stem cell maintenance. Transcriptional target
genes of β-catenin involve several EMT-promoting genes,
including Slug. Expression of Slug has been shown to be
associated with breast tumor recurrence and metastasis
[13-15]. Pro-migratory transcription factor Slug (EMT-
TF), which can repress E-cadherin, triggers the steps of
desmosomal disruption, cell spreading, and partial separ-
ation at cell-cell borders, which comprise the first and ne-
cessary phase of the EMT process [16].
Recently, the use of natural phytochemicals to impede
tumor metastasis via multiple targets that regulate the
migration potential of tumor cells has gained immense
importance [17]. In this regard, curcumin, a dietary poly-
phenol, has been studied extensively as a chemopreven-
tive agent in a variety of cancers, including those of thebreast, liver, prostate, hematological, gastrointestinal, and
colorectal cancers, and as an inhibitor of metastasis [18].
In a recent report, curcumin was shown to selectively in-
hibit the growth and self-renewal of breast CSCs (bCSCs)
[19]. However, there are no reports regarding the contri-
bution of curcumin in bCSC migration.
The present study describes (i) the mechanisms govern-
ing the augmented migration potential of bCSCs, which (ii)
possibly associates with tumor aggressiveness and is largely
attributable to the inherent downregulation of the anti-
migratory tumor suppressor protein, E-cadherin, in bCSCs,
and (iii) the role of curcumin in modulating the same. A
search for the upstream mechanism revealed higher nu-
clear translocation and transcriptional activity of β-catenin
resulting from disruption of E-cadherin/β-catenin com-
plex formation in bCSCs in comparison with non-stem
tumor cells. Upregulation of nuclear β-catenin resulted in
the augmentation of Slug gene expression that, in turn, re-
pressed E-cadherin expression. In contrast, exposure to
curcumin inhibited the nuclear translocation of β-catenin,
thereby hampering the activation of its EMT-promoting
target genes, including Slug. Resultant upregulation of E-
cadherin led to increase in E-cadherin/β-catenin complex
formation, which further inhibited nuclear translocation of
β-catenin. As a consequence, the E-cadherin/β-catenin
negative feedback loop was amplified upon curcumin ex-
posure, which reportedly inhibits EMT on one hand and
promotes cell-cell adherens junction formation on the
other. These results suggest that curcumin-mediated in-
hibition of bCSC migration may be a possible way for




Primary human breast cancer tissue samples used in this
study were obtained with informed consent from all pa-
tients from Department of Surgery, Bankura Sammilani
Medical College, Bankura, India, in accordance with the
Institutional Human Ethics Committee (approval letter
CNMC/ETHI/162/P/2010), and the associated research
and analyses were done at Bose Institute, Kolkata, India,
in compliance with the Bose Institute Human Ethics
Committee (approval letter BIHEC/2010-11/11). These
tumors were exclusively primary-site cancers that had
not been treated with either chemotherapy or radiation.
The selected cases consisted of three primary breast can-
cer patients of each group. The specimens were washed
with phosphate-buffered saline (PBS), cut into small
pieces (5 × 5 mm in size), and immersed in a mixture of
colloagenase (10%; Calbiochem, now part of EMD
Biosciences, Inc., San Diego, CA, USA) and hyaluroni-
dase (0.5 mg/mL; Calbiochem) for 12 to 16 hours at 37°C
on orbital shaker. The contents were centrifuged at 80 g for
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prising mammary fibroblasts, was discarded, and to the
pellet pre-warmed 0.125% trypsin-EDTA was added. The
mixture was gently pipetted and kept for 30 minutes at
37°C. Finally, the pellet obtained was washed with cold
Hanks’ buffer saline with 2% fetal bovine serum and cen-
trifuged at 450 g for 5 minutes at room temperature. The
single cells were seeded on poly-L lysine-coated dishes
and cultured in medium containing growth factors, 0.1
ng/mL human recombinant epidermal growth factor, 5
μg/mL insulin, 0.5 μg/mL hydrocortisone, 50 μg/mL gen-
tamycin, 50 ng/mL amphotericin-B, and 15 μg/mL bovine
pituitary extract at 37°C. Medium was replaced every 4
days, and passages were done when the cells reached 80%
confluence [20].Cell culture and treatment
Human breast cancer cell lines MCF-7 and T47D were ob-
tained from the National Centre for Cell Science (Pune,
India). The cells were routinely maintained in complete
Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS), penicillin (100 units/mL), and streptomycin (100 l g/
mL) at 37°C in a humidified incubator containing 5% CO2.
Cells were allowed to reach confluency before use. Cells
were maintained in an exponential growth phase for all ex-
periments. All cells were re-plated in fresh complete
serum-free medium for 24 hours prior to the experiments.
Viable cell numbers were determined by Trypan blue dye
exclusion test [21]. Cells were treated with different doses
(5, 10, 15, and 20 μM) of curcumin (Sigma-Aldrich,
St. Louis, MO, USA) for 24 hours to select the optimum
non-apoptotic dose of curcumin (15 μm) which signifi-
cantly abrogates migration potential of bCSCs. An equiva-
lent amount of carrier (dimethyl sulfoxide) was added to
untreated/control cells. To rule out cell proliferation, all
migration assays were performed in the presence of 10 μg/
mL mitomycin C.Mammosphere culture
For mammosphere culture, MCF-7/T47D cells were
seeded at 2.5 × 104 cells per well in sixwell Ultralow
Adherence plates (Corning Inc., Corning, NY, USA) in
DMEM/F12 with 5 μg/mL bovine insulin (Sigma-Aldrich),
20 ng/mL recombinant epidermal growth factor, 20 ng/
mL basic fibroblast growth factor, B27 supplement (BD
Biosciences, San Jose, CA, USA), and 0.4% bovine serum
albumin (BSA) as previously described [22]. Primary/1°
and secondary/2° mammosphere formation was achieved
by using weekly trypsinization and dissociation followed
by reseeding in mammosphere media at 2.5 × 104 cells per
well into Ultralow Adherence sixwell plates.Cell viability assay
Cell viability assay was performed by using Trypan blue
dye exclusion assay. Mammospheres were treated with dif-
ferent doses of curcumin for 24 hours. Thereafter, the
numbers of viable cells were counted by Trypan blue dye
exclusion by using a hemocytometer. The results were
expressed as percentage relative to the control cells.
Flow cytometry
Expression of human bCSC markers CD44 and CD24 were
analyzed by flow cytometric study in different stages of
breast cancer tissue as well as in MCF-7/T47D cells and
primary and secondary mammospheres by using CD44-
FITC and CD24-PE antibodies (BD Biosciences). bCSCs
were flow-cytometrically sorted from primary breast tumors
on the basis of the cell surface phenotype CD44+/CD24−/low.
De-differentiation, drug resistance, and stemness phenom-
ena were quantified flow-cytometrically by measuring mean
fluorescence intensities of de-differentiation markers Oct-4-
PerCP-Cy5.5, Nanog-PE, and Sox-2-Alexa Fluor-647;
drug-resistance markers MRP1-FITC, ABCG2-PE, and
ALDH1-FITC (BD Biosciences); and epithelial markers
cytokeratin-18-PE and cytokeratin-19-PE (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA). Expression
levels of E-cadherin, β-catenin, and Slug (Santa Cruz
Biotechnology, Inc.) were determined with respective
primary antibodies conjugated with PE as previously
described [23].
Immunofluorescence
For immunofluorescence, cells were grown on sterile glass
coverslips at 37°C for 24 hours. Cells after treatment were
washed briefly with PBS and fixed with 4% formaldehyde
for 20 minutes at 37°C and permeabilized with Triton
X100 (for intracellular protein expression analysis). There-
after, cells were blocked for 2 hours in a blocking buffer
(10% BSA in PBS) and incubated for another hour in PBS
with 1.5% BSA containing anti-CD44/CD24/E-cadherin/β-
catenin/phospho-FAK antibody (Santa Cruz Biotechnol-
ogy, Inc.). After washing in PBS, cells were incubated with
FITC/PE-conjugated secondary antibodies in PBS with
1.5% BSA for 45 minutes at 37°C in the dark. 4′-6-diami-
dino-2-phenylindole (DAPI) was used for nuclear staining.
Coverslips were washed with PBS and mounted on mi-
croscopy glass slides with 90% glycerol in PBS. Images
were acquired by using a confocal microscope (Carl Zeiss,
Jena, Germany) [21].
Wound-healing assay
To determine the expression of bCSC markers in the mi-
grating versus non-migrating fraction of MCF-7 cells, bi-
directional wound-healing assay was performed. Briefly,
cells were grown to confluency on sterile glass coverslips,
after which a sterile 10-μL tip was used to scratch the
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were allowed to migrate for 24 hours and then the cover-
slips were used for immunofluorescence staining.
Transwell migration assay
Transwell migration assay was performed by using 8.0-
μm cell culture inserts (BD Biosciences) to test the mi-
gratory ability of primary breast cancer cells, MCF-7/
T47D cells, and mammosphere-forming cells. Cells were
seeded at 2.5 × 105 cells per well in serum-free DMEM
in the upper chamber of 12-well plates and allowed to
migrate for 8 hours toward DMEM containing 10% FBS
in the lower chamber. After 8 hours, the cells in the
upper chamber were removed with a cotton swab and
the migrated cells in the lower surface of the membrane
were fixed and stained with giemsa or the migrated frac-
tion of 2° mammospheres were collected from the
under-surface of the membranes after 24-hour migration
assay for flow cytometry. Images were acquired with a
brightfield microscope (Leica, Wetzlar, Germany) at 20×
magnification. To quantify migratory cells, three independ-
ent fields were analyzed by using ImageJ software (National
Institutes of Health, Bethesda, MD, USA). Migration was
expressed as percentage of cells migrated. For the same, the
percentage of cells that migrated in the control set of each
relevant experiment was taken as 100%.
Cell adhesion assay
For evaluating cell adhesion property, cells were trypsi-
nized by using trypsin-EDTA and resuspended in DMEM
at a density of 0.8 × 106 cells per milliliter. These cell sus-
pensions were allowed to recover from the trypsinization
for 1 hour at 37°C in a humidified incubator containing
5% CO2. They were mixed gently every 15 minutes during
this hour of conditioning. After every 15 minutes of incu-
bation, the dishes were removed from the incubator, and
the medium containing unattached cells was removed. Im-
ages were acquired with an Olympus BX700 inverted
microscope (Olympus, Tokyo, Japan) at 20× magnifica-
tion. To quantify cell adhesion, the number of unattached
cells at 1 hour was determined by counting three inde-
pendent fields. Attachment (at 1 hour) was expressed as
percentage of cells adhered, and the percentage of the
control set of each relevant experiment was taken as
100%.
Cell spreading assay
Spreading of the attached cells was monitored. At various
time intervals (for every 30 minutes up to 3 hours), cells
were imaged by using an Olympus BX700 inverted micro-
scope (Olympus). Images of multiple fields were captured
from each experimental set at 40× magnification. From
the phase-contrast images, individual cell boundaries were
marked with the free-hand tool of ImageJ, and the areawithin the closed boundary of each cell was quantified by
using the analysis tool of ImageJ. Cell spreading (at 3
hours) was expressed as mean circularity of the cells. As
confirmation assay for cell adhesion and spreading, MCF-
7 cells and 2° mammosphere cells were plated on fibro-
nectin (50 μg/mL)-coated surface, and focal adhesions
were stained and quantified by immunofluorescence stain-
ing for phospho-FAK. In fact, phospho-FAK-enriched
clusters at lamellipodia were considered as focal adhesion
complex. Focal adhesion segmentation and size measure-
ment were done by using ImageJ software.Three-dimensional invasion assay
Three-dimensional (3D) invasion assay of mammospheres
was performed in 96-well plates. Each well was first coated
with 80 μL matrigel (BD Biosciences) in 3:1 ratio with
complete DMEM. Mammospheres with or without curcu-
min/small interfering RNA (siRNA)/short hairpin RNA
(shRNA)/cDNA treatment were mixed with matrigel (6:1)
and added to the previously coated wells. Thereafter, the
mammospheres were allowed to invade for 48 hours. Im-
ages were photographed by using an Olympus BX700
inverted microscope (Olympus) at 20× magnification.
Data were analyzed by using ImageJ software as area in-
vaded and were expressed as percentage relative to the
control set, the value of which was taken as 100%.Western blotting and co-immunoprecipitation
To obtain whole cell lysates, cells were homogenized in
buffer (20 mM Hepes, pH 7.5, 10 mM KCl, 1.5 mM MgCl2,
1 mM Na-EDTA, 1 mM Na-EGTA, and 1 mM DTT). All
buffers were supplemented with protease and phosphatase
inhibitor cocktail [24,25]. Protein concentrations were
estimated by using Lowry’s method. An equal amount of
protein (50 μg) was loaded for Western blotting. For direct
Western blot analysis, the cell lysates or the particular
fractions were separated by SDS-PAGE, transferred to
polyvinylidene difluoride membrane (Millipore, Darmstadt,
Germany), and probed with specific antibodies like anti-E-
cadherin, anti-β-catenin, anti-histone H1, anti-cyclin-D1,
anti-c-myc, anti-slug, anti-vimentin, anti-MMP-2, anti-
MMP-9, anti-twist, anti-Snail, and anti-α-Actin (Santa
Cruz Biotechnology, Inc.). The protein of interest was visu-
alized by chemiluminescence (GE Biosciences, Piscataway,
NJ, USA). To study the interaction between E-cadherin
and β-catenin, β-catenin immunocomplex from whole cell
lysate was purified by using β-catenin antibody and protein
A-Sepharose beads (Invitrogen, Frederick, MD, USA).
The immunopurified protein was immunoblotted with
E-cadherin antibody. The protein of interest was visual-
ized by chemi-luminescence. Equivalent protein loading
was verified by using anti-α-actin/Histone H1 antibody
(Santa Cruz Biotechnology, Inc.) [26].
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Two micrograms of the total RNA, extracted from cells
with TRIzol reagent (Invitrogen, Carlsbad, CA, USA), was
reverse-transcribed and subjected to polymerase chain re-
action (PCR) with enzymes and reagents of the RTplusPCR
system (Eppendorf, Hamburg, Germany) by using Gen-
eAmpPCR 2720 (Applied Biosystems, Foster City, CA,
USA). The cDNAs were amplified with specific primers
for E-cadherin (forward-CACCTGGAGAGAGGCCATGT,
reverse-TGGGAAACAT-GAGCAGCTCT) and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) (forward-
CGT-ATTGGGCGCCTGGTCAC, reverse-ATGATGAC
CCTTT-TGGCTCC).Plasmid and small interfering RNA/short hairpin RNA
transfections
Cells were transfected separately with 300 pmol of E-
cadherin shRNA (Addgene, Cambridge, MA, USA) or
Slug siRNA (Santa Cruz Biotechnology, Inc.) by using
Lipofectamine 2000 (Invitrogen). The levels of respective
proteins were estimated by Western blotting. The Slug
cDNA (Addgene) plasmid was used for overexpression
studies. The Slug cDNA clone was introduced in cells by
using Lipofectamine 2000. Stably expressing clones were
isolated by limiting dilution and selection with G418
sulphate (Cellgro, a brand of Mediatech, Inc., Manassas,
VA, USA) at a concentration of 400 μg/mL, and cells
surviving this treatment were cloned and screened by
Western blot analysis with specific antibodies.Immunohistochemistry
Tissues were dissected out; fixed in Bouin’s fixative over-
night; cryoprotected in 10% (2 hours), 20% (2 hours),
and 30% (overnight) sucrose solution in PBS at 4°C; and
frozen with expanding CO2, and serial sections were cut
on a cryostat (CM1850; Leica) at 15-μm thickness. The
tissue sections were washed in PBS (pH 7.45) for 15 mi-
nutes and treated with 1% BSA in PBS containing 0.1%
Triton X-100. Sections were incubated overnight at 25°C
in a humid atmosphere with primary antibodies against
E-cadherin (1:100; Santa Cruz Biotechnology, Inc.) di-
luted in PBS containing and 1% BSA. Sections were
rinsed in PBS for 10 minutes and incubated with
biotinylated anti-mouse IgG (Sigma-Aldrich; 1:100) for
1 hour, followed by ExtrAvidin-peroxidase conjugate
(Sigma-Aldrich; 1:100) for 40 minutes. 3-Amino-9-ethyl
carbazole was used as chromogen (Sigma-Aldrich; 1:100)
to visualize the reaction product. Thereafter, sections
were counterstained with hematoxylin (1:1; Himedia,
Mumbai, India). Finally, sections were washed in dis-
tilled water and mounted in glycerol gelatin. Images
were acquired with a brightfield microscope (Leica) at
10× magnification.Statistical analysis
Values are shown as standard error of mean unless other-
wise indicated. Comparison of multiple experimental
groups was performed by two-way analysis-of-variance
test. Data were analyzed; when appropriate, significance of
the differences between mean values was determined by a
Student’s t test. Results were considered significant at a P
value of not more than 0.05.
Results
Breast cancer stem cells, being highly migratory, are
linked with aggressiveness of the disease
To determine whether CSCs are linked with tumor ag-
gressiveness or malignancy, we performed flow cytometric
analyses of bCSC markers CD44+/CD24−/low in patient-
derived tumor samples of different stages. We also tested
the migratory potentials of these primary cells of different
stages of cancer by performing transwell migration assay.
Interestingly, along with the gradual increase in percent-
age cell migration, that is, 188.67% ± 9.33% (P <0.001) and
337.33% ± 20.34% (P <0.001) in stages II and III, respect-
ively, as compared with stage I, which was taken as 100%,
there was increase in the CSC content too, that is, 4.2% ±
0.40%, 14.17% ± 0.75%, and 21.13% ± 1.80% CSCs (P <0.001)
in stages I, II, and III, respectively (Figure 1A and B), indi-
cating that the CSC population is proportionally related
with breast cancer migration. In a parallel experimental
set using the razor-wound migration assay method, hu-
man breast cancer cell line MCF-7 furnished higher ex-
pression of CSC-markers (that is, CD44+/CD24−/low) in
the migrating population as compared with the non-
migrating fraction of cells as evident from our confocal
data (Figure 1C). In line with an earlier report [27], these
results revealed that the increase in expression of CSC
markers selects for breast cancer cells with enhanced ma-
lignant and metastatic ability.
Our next attempt was to evaluate the migratory prop-
erties of bCSCs as compared with the non-stem tumor
population. For the same, the percentage CSC content
of MCF-7 and T47D, as well as of primary/1° and sec-
ondary/2° mammospheres generated from these two cell
lines, was elucidated by using flow cytometry for the
bCSC phenotype, CD44+CD24−/low. Results of Figure 2A
depict the presence of 4.3% ± 0.70% CSCs in MCF-7,
26.72% ± 2.40% in its 1° mammosphere, and 52.17% ±
2.86% in 2° mammosphere (P <0.001), and the percent-
ages were 2.04% ± 0.49% in T47D, 25.44% ± 2.32% in its
1° mammosphere, and 57.47% ± 4.02% in 2° mammosphere
(P <0.001). Since 2° mammospheres were found to be
highly CSC-enriched, all of our later studies for bCSCs
were performed with 2° mammospheres. Next, we re-
confirmed the presence of significantly higher stemness
properties in the mammospheres as compared with
MCF-7/T47D cells by comparing the expression levels
Figure 1 Breast cancer stem cells (CSCs) are highly migratory and are correlated with aggressiveness of the disease. (A) The percentage
content of breast CSCs (CD44+/CD24−/low) in different stages of breast cancer was determined by flow cytometry and represented graphically (right
panel). The left panel depicts representative flow cytometry data. (B) Migration of primary breast cancer cells of different stages was evaluated by
using transwell migration assay. Cells that had migrated to the lower surface of the 8.0-μm membrane were stained with Giemsa stain, counted, and
represented graphically (right panel). The left panel shows brightfield images of migration assay of different breast cancer stages. (C) Expression of
CSC markers (CD44+/CD24−/low) was visualized by immunofluorescence in the migrating front and non-migrating pool of MCF-7 cells after 24-hour
wound-healing assay. Data are presented as mean ± standard error of mean or representative of three independent experiments.
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(Figure 2B); de-differentiation and drug-resistance markers,
ABCG2 and MRP1 (Figure 2C); and ALDH1 (Figure 2D).
After the presence of higher stemness and CSC enrichment
in the mammospheres of both the breast cancer cell linesMCF-7 and T47D was validated, all of our later experi-
ments were performed with mammospheres of MCF-7 cells
while re-confirming the key experiments in mammospheres
of T47D cells. Next, we compared the migration efficiency
of mammospheres with MCF-7 cells. Interestingly, these
Figure 2 Relative quantification of breast cancer stem cells in MCF-7 and T47D cell lines and their mammospheres along with their
characterization for stemness properties. (A) The percentage content of breast cancer stem cells (CD44+/CD24−/low) in MCF-7 and T47D cells,
MCF-7/T47D-derived primary/1° and secondary/2° mammospheres, were determined by flow cytometry and represented graphically (right panel).
The left panel depicts representative flow cytometry data. (B-D) Graphical representation of relative mean fluorescence intensities (MFIs) in
arbitrary units (AU) of de-differentiation markers Oct-4, Sox-2, and Nanog; drug-resistance markers ABCG2 and MRP1; and stemness-related
enzyme ALDH1 in MCF-7 and T47D cell lines, along with their respective 2° mammospheres as determined by flow cytometry (right panels).
The left panels depict representative flow cytometric histogram overlay data. Data are presented as mean ± standard error of mean or
representative of three independent experiments.
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migratory as compared with MCF-7 cells within the same
time frame. Briefly, mammosphere-forming cells exhibited
higher adhesion property than MCF-7 cells; that is, 316% ±
18.19% mammosphere-forming cells were adhered as
compared with MCF-7 cells (100%) (P <0.001; Figure 3A).
Similarly, mammosphere cells demonstrated lesser circu-
larity (0.503 ± 0.04 mean circularity) than MCF-7 cells(0.873 ± 0.04 mean circularity), thereby depicting higher
mesenchymal and migration properties of mammospheres
(P <0.01; Figure 3B). At this juncture, for more robust as-
sessment of adhesion, we quantified the size of phospho-
FAK-enriched focal adhesion area from the lammellipodia
of MCF-7 and its 2° mammosphere-forming cells. Our
results showed that the mean focal adhesion area of
mammosphere-forming cells was significantly higher
Figure 3 Breast cancer stem cell (CSC)-enriched mammospheres exhibit highly aggravated migratory properties. (A, B) Representative
phase-contrast images of cell adhesion and spreading assays of MCF-7 and 2° mammosphere-forming cells (left panels). The right panels
demonstrate relative quantification of the data. (C) Confocal images showing focal adhesions in MCF-7 and 2° mammosphere-forming cells,
stained with phospho-FAK (PE) (red) and nuclear stain 4′-6-diamidino-2-phenylindole (DAPI) (left panel). The right panel illustrates relative
quantification data of mean focal adhesion area. (D) Representative brightfield images of transwell migration assays of MCF-7 and T47D cells
and their respective 2° mammosphere-forming cells (left and middle panels). The right panel demonstrates relative quantification of the data graphically.
(E) The percentage content of breast CSCs (CD44+/CD24−/low) in the migrated fractions of 2° mammospheres of MCF-7 and T47D cell lines as compared
with non-stem cancer cells (NSCCs) was determined by flow cytometry and represented graphically (right panel). The left panel depicts representative
flow cytometry data. Data are presented as mean ± standard error of mean or representative of three independent experiments.
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(Figure 3C). Even in transwell migration assay, the per-
centage migration of mammosphere cells (293.67% ±
9.56%) was higher than that of MCF-7 cells (taken as 100%)
(P <0.001; Figure 3D). Results of Figure 3D validated thefindings of transwell migration assay in the T47D cell line
and its mammospheres.
At this stage, we considered the possibility that, since
the mammosphere is a heterogeneous population of
cells consisting of both CSCs and non-stem cancer
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might be a heterogeneous one. It therefore becomes
debatable whether the aggravated migration property of
mammospheres is the contribution of bCSCs or of
non-stem cancer cells. To get the answer, the migrated
cells of the mammospheres were collected from the
under-surface of the membranes, and flow cytometric
analyses were performed to characterize the migrated
cells. Results of Figure 3E demonstrated that the major-
ity of the migrating cells of the mammospheres were
bCSCs for both the cell lines, that is, 83.67% ± 2.90%
bCSCs for mammospheres of MCF-7 (P <0.001) and
80.33% ± 3.48% (P <0.001) bCSCs for mammospheres
of T47D. These results validate that bCSCs are endowed
with aggravated migration potential as compared with the
rest of the non-stem tumor population.
bCSCs exhibit enhanced migration potential through
suppression of the EMT marker, E-cadherin
Our effort to delineate the mechanism underlying the
enhanced migratory behavior of bCSCs revealed suppres-
sion of E-cadherin expression, loss of which (a hallmark of
EMT) has been reported to promote tumor metastasis
[28]. In fact, our immunohistochemical analyses revealed a
gradual decrease in the expression levels of E-cadherin
protein with increasing stages of breast cancer (Figure 4A).
Results of our Western blot and reverse transcription-
PCR analyses also elucidated lower protein and mRNA
levels of E-cadherin in mammospheres than in MCF-7
cells (Figure 4B). The same results were obtained in our
confocal analyses (Figure 4C). In our previous findings, we
have shown an increase in CSC percentage with an in-
crease in the stage of breast cancer (Figure 1A). Therefore,
we postulated that probably bCSCs maintain their aggra-
vated migration property through suppression of the
E-cadherin protein expression. As a validation of this
hypothesis, shRNA-mediated silencing of E-cadherin pro-
tein expression in mammospheres resulted in significant
augmentation of the migratory phenotype of these mam-
mospheres, as reflected in our cell-adhesion assay; that is,
316.67% ± 23.33% E-cadherin-silenced mammosphere cells
adhered as compared with the control shRNA-transfected
cells (100%) (P <0.001; Figure 4D, left panel). Similarly,
E-cadherin-ablated mammospheres demonstrated aug-
mented cell spreading as depicted by loss in mean circu-
larity of cells: that is, 0.45 ± 0.02 and 0.27 ± 0.03 mean
circularity of cells of control shRNA-transfected and
E-cadherin-silenced mammospheres, respectively (P <0.01;
Figure 4D, right panel). In addition, 3D invasion potential
of E-cadherin-knocked-down mammospheres was also
elevated (161.67% ± 7.31%) when compared with control
shRNA-transfected set (100%) (P <0.001; Figure 4E, left
panel). These results were finally confirmed in our trans-
well migration assay in which E-cadherin-shRNA-transfected mammosphere cells showed 340.67% ± 26.97%
migration as compared with 100% migration of control
shRNA-transfected cells (P <0.001; Figure 4E, right panel).
Transwell migration assay of mammospheres of T47D
cells also rendered similar results: that is, 291.67% ± 15.41%
cell migration in E-cadherin-shRNA transfected mammo-
spheres as compared with 100% cell migration in control
shRNA set (P <0.001; Figure 4E, right panel). Taken
together, these results validate that suppressed expression
of E-cadherin is essential for maintaining accentuated
migration potential of bCSCs.
Suppression of E-cadherin expression in bCSCs is associated
with greater nuclear translocation and transcriptional activity
of β-catenin
There are several reports delineating the pro-migratory
role of β-catenin protein [29,30]. Moreover, activation of
β-catenin pathway has been reported in CSCs [31]. Under
normal conditions, β-catenin exists in physical association
with membrane-bound E-cadherin. However, if unbound
with surface E-cadherin, β-catenin becomes free to trans-
locate to the nucleus and transcriptionally activates several
pro-migratory genes necessary for EMT in association
with the TCF/LEF transcription factors [12]. Results of our
co-immunoprecipitation studies revealed a much lower
association between E-cadherin and β-catenin proteins
in mammospheres as compared with MCF-7 cells
(Figure 5A). Moreover, although the total β-catenin pro-
tein level remained unaltered, a significantly higher nu-
clear level of the protein was observed in mammospheres
than MCF-7 cells (Figure 5B). Higher nuclear localization
of β-catenin in mammospheres was confirmed by confocal
microscopy (Figure 5C). That the transcriptional activity
of β-catenin was augmented in mammospheres was
confirmed in our Western blotting data, in which greater
expression of cyclin-D1, c-myc, and Slug proteins
(Figure 5D), which are direct transcriptional targets of
β-catenin [12], was observed. However, the expression
levels of another important β-catenin transcriptional
target, Snail, not only was very low in both MCF-7 cells
and its mammospheres but also failed to show any signifi-
cant difference between these two cell types (Figure 5D).
Cumulatively, these results validate that the higher pro-
migratory milieu in bCSCs results from greater transcrip-
tional activity of β-catenin.
Activation of β-catenin/Slug pathway hinders expression
of E-cadherin in bCSCs
It is reported that both the EMT-promoting transcription
factors, Slug and Snail, the transcriptional target genes of
β-catenin, are potent transcriptional repressors of the
E-cadherin gene [32]. Our results above, showing signifi-
cantly greater Slug gene expression in mammospheres
than in MCF-7 cells with very low expression levels of
Figure 4 (See legend on next page.)
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Figure 4 The augmented migration potential of breast cancer stem cells (bCSCs) results from the suppression of the epithelial-mesenchymal
transition (EMT) marker, E-cadherin. (A) Immunohistological staining for E-cadherin (brown color for antibody staining and counterstained with
hematoxylin) of breast tumor samples. (B) Protein and mRNA expression profiles of E-cadherin in MCF-7 cells, 1° and 2° mammospheres, was determined
by Western blotting (WB) (upper panel) and reverse transcription-polymerase chain reaction (RT-PCR) (lower panel). (C) Expression of E-cadherin in MCF-7
cells and 2° mammospheres was visualized by immunofluorescence. (D) Graphical representation of relative cell adhesion (left panel) and spreading (right
panel) of MCF-7-derived 2° mammospheres with or without transfection with E-cadherin-short hairpin RNA (shRNA). The efficiency of transfection was
assessed by evaluating the expression of E-cadherin through WB (inset). (E) A similar experimental setup was scored for three-dimensional (3D) invasion
(left panel) and transwell migration (right panel) assays. Transwell migration assay was performed under similar experimental conditions in T47D-derived
2° mammospheres (right panel). α-Actin/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal loading control. Data are presented
as mean ± standard error of mean or representative of three independent experiments.
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whether the repression of E-cadherin in bCSCs was
mediated through the β-catenin/Slug pathway. To that
end, siRNA-mediated silencing of Slug in mammo-
spheres resulted in restoration of E-cadherin expression
at both protein and mRNA levels (Figure 5E). Under
such conditions, the migration potential of the mammo-
spheres was simultaneously retarded as was assessed by
monitoring (i) adhesion, that is, 52.67% ± 5.61% cells
adhered in Slug-silenced mammospheres as compared
with the control set (100%, P <0.01) (Figure 5F); (ii)
spreading, that is, 0.49 ± 0.03 and 0.7 ± 0.04 mean
circularity in control and Slug-ablated mammospheres,
respectively (P <0.05; Figure 5G, left panel); (iii) inva-
sion, that is, 46.67% ± 4.05% invasion in Slug-siRNA-
transfected mammospheres as compared with control,
that is, (100%, P <0.001) (Figure 5G, middle panel); and
(iv) transwell migration, that is, 37.33% ± 5.04% in Slug
knocked-down mammospheres as compared with 100%
migration of the control (P <0.001; Figure 5G, right
panel) of MCF-7 cells. The effect of Slug silencing in
migration potential was further validated in mammo-
spheres of T47D cells (28% ± 5.69% migration as
compared with control, P <0.001, Figure 5G, right
panel). All of these results confirmed that E-cadherin
repression in bCSCs results from the activation of the
β-catenin/Slug pathway.
Curcumin abrogates bCSC migration in a dose-dependent
manner by restoring EMT-suppressor, E-cadherin
The phytochemical curcumin is a known repressor of
several tumor properties, including tumor cell migration
[18]. Additionally, several recent studies suggest that CSCs
could be targeted by using curcumin [33-35]. However,
there are no detailed studies on the anti-migratory role of
curcumin in CSCs. Results of our transwell migration assay
revealed that 24-hour curcumin treatment inhibits
migration of bCSC-enriched mammospheres of both
MCF-7 and T47D cells in a dose-dependent manner
(Figure 6A). Our cell viability assay data showed that
curcumin exerted apoptotic effects on mammospheres
of both MCF-7 and T47D cells beyond a 15 μM dose(Additional file 1: Figure S1). Therefore, to avoid the
possibility of curcumin-induced cell death in our ex-
perimental set-up, further experiments were restricted
to the 15 μM dose of this phytochemical. Additional
validation of the effects of curcumin on adhesion, spread-
ing, and 3D invasion properties of mammospheres—that
is, 26% ± 3.46% cell adhesion, P <0.001 (Figure 6B) and
44% ± 4.36% invasion, P <0.001 (Figure 6D) as compared
with 100% value of the respective control sets, and 0.46 ±
0.02 and 0.80 ± 0.05 mean circularity (Figure 6C) in con-
trol and curcumin-treated mammospheres, respectively
(P <0.01)—confirmed the anti-migratory effects of cur-
cumin on bCSCs. In fact, curcumin treatment resulted
in upregulation of E-cadherin expression at both pro-
tein and mRNA levels in mammosphere-forming cells
(Figure 6E). To find out whether curcumin exposure
altered only E-cadherin expression or overall epithelial
characteristics of these bCSCs, flow cytometric analyses
of other epithelial markers cytokeratin-18 and -19 were
performed. The results revealed that curcumin aug-
mented the overall epithelial characteristics of these
cells (Figure 6F). On the other hand, silencing E-
cadherin expression by using shRNA significantly nulli-
fied the effects of curcumin on the various migratory
phenotypes of these CSCs, namely, cell adhesion
(351.67% ± 10.14%), 3D invasion (174% ± 7.37%), and
migration (304.67% ± 23.79%), as compared with the
value of 100% of the respective control sets (P <0.001
in each case) (Figure 6G). The results of mean circular-
ity of control (0.463 ± 0.03) and E-cadherin shRNA-
transfected mammospheres (0.276 ± 0.03) of MCF-7
cells (P <0.05; Figure 6G) were in line with these findings
that silencing E-cadherin expression significantly nullified
the effects of curcumin on various migratory pheno-
types of these CSCs. These results were validated in
T47D cells in which higher migration of E-cadherin
shRNA-transfected cells of mammospheres (281.67% ±
14.81%) was observed in comparison with untransfected
ones (100%, P <0.001; Figure 6H). These results
together indicated that curcumin inhibited bCSC mi-
gration property by restoration of the EMT-suppressor,
E-cadherin.
Figure 5 E-cadherin suppression in breast cancer stem cells (bCSCs) is associated with greater nuclear translocation of β-catenin and
subsequent trans-activation of Slug. (A) β-catenin-associated E-cadherin was assayed by co-immunoprecipitation from cell lysates of MCF-7 and
2° mammospheres by using specific antibodies (left panel) or with normal human immunoglobulin G (IgG) as a negative control (right panel). To
ensure comparable protein loading, 20% of supernatant from immunoprecipitation (IP) sample was subjected to determination of α-actin by Western
blotting (WB). (B) WB was conducted to study the levels of total β-catenin and nuclear β-catenin in MCF-7 and 2° mammospheres for determining the
nuclear translocation of β-catenin. (C) The relative nuclear expression of β-catenin in MCF-7 and 2° mammospheres was visualized by immunofluorescence.
(D) WB was performed to study the expression levels of β-catenin target genes Cyclin-D1, c-Myc, Slug and Snail in MCF-7 cells and 2° mammospheres.
(E) Protein and mRNA expression profiles of E-cadherin in 2° mammospheres of MCF-7 cells with or without transfection with Slug-short interfering RNA
(siRNA) were determined by WB (right panel) and reverse transcription-polymerase chain reaction (RT-PCR) (left panel). The efficiency of transfection was
assessed by evaluating the expression of Slug through WB (inset). (F, G) Graphical representation of relative cell adhesion, spreading, three-dimensional
invasion, and transwell migration of MCF-7-derived 2° mammospheres with or without transfection with Slug siRNA. Transwell migration assay was also
performed under similar experimental conditions in T47D-derived 2° mammospheres (G, right panel). α-Actin/histone H1/glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as an internal loading control. Data are presented as mean ± standard error of mean or representative of three
independent experiments.
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bCSCs thereby restoring E-cadherin
Since curcumin is reported to be a repressor of β-catenin
activity [36], we next attempted to explore whether
curcumin could tamper the functioning of β-catenin in
bCSCs. Our co-immunoprecipitation studies revealed that
curcumin treatment results in significant elevation of E-
cadherin/β-catenin complex formation in mammospheres
(Figure 7A). A further search for the underlying reason ex-
posed inhibition of the nuclear translocation of β-catenin
protein upon curcumin treatment, although the phyto-
chemical failed to alter the total protein level of β-catenin(Figure 7B). This result was confirmed by confocal micros-
copy (Figure 7C). That curcumin treatment diminished
the transcriptional function of β-catenin was evident from
our Western blot data in which curcumin-treated mam-
mospheres expressed lower protein levels of its transcrip-
tional targets cyclin D1, c-myc, and Slug, whereas no
detectable change was observed in case of Snail, the ex-
pression level of which was already very low (Figure 7D).
Furthermore, our Western blot data depicted curcumin-
mediated downregulation of other β-catenin-induced
EMT-promoting factors like vimentin [37] and MMP-2
and MMP-9 [12] in mammospheres (Figure 7E).
Figure 6 (See legend on next page.)
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Figure 6 Curcumin abrogates breast cancer stem cell migration by restoration of E-cadherin expression. (A) Graphical illustration of
transwell migration assay performed to study the effects of 24-hour curcumin treatment on migration of 2° mammosphere-forming cells of
MCF-7 and T47D cell lines in a dose-dependent manner (right panels). Representative brightfield images are provided in the left panels. (B-D)
Representative phase-contrast images of cell adhesion, spreading, and three-dimensional (3D) invasion assays of 2° mammospheres of MCF-7 cell
line with or without curcumin treatment (left panels) along with their graphical quantifications (right panels). (E) Protein and mRNA expression
profiles of E-cadherin in 2° mammospheres of MCF-7 cell line with or without curcumin treatment were determined by Western-blotting (left
panel) and reverse transcription-polymerase chain reaction (RT-PCR) (right panel). (F) Graphical representation of relative mean fluorescence
intensities (MFIs) in arbitrary units (AU) of epithelial markers cytokeratins 18 and 19 in 2° mammospheres of MCF-7 cell line with or without
curcumin treatment were determined by flow cytometry and represented graphically (right panel). The left panel depicts representative flow
cytometric histogram overlay data. (G) Graphical quantifications of cell adhesion, spreading, 3D invasion, and transwell migration assays of
MCF-7-derived 2° mammospheres with or without curcumin and E-cadherin-short hairpin RNA (shRNA) treatment/transfection. (H) Transwell
migration assay was performed under similar experimental conditions as mentioned above in T47D-derived 2° mammospheres. α-Actin/glyceraldehyde
3-phosphate dehydrogenase (GAPDH) was used as an internal loading control. Data are presented as mean ± standard error of mean or representative of
three independent experiments. Cont, control; Cur, curcumin.
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us to verify whether curcumin-mediated restoration of
E-cadherin expression was due to the suppression of the
β-catenin/Slug pathway. Our results indicated that trans-
fection of mammosphere-forming cells with Slug overex-
pression clone significantly downregulated curcumin effect
on E-cadherin protein expression (Figure 7F) and consider-
ably nullified curcumin-mediated abrogation of MCF-7-
derived bCSC migration as evident from our adhesion,
spreading, 3D invasion, and migration assays (Figure 7G).
These results were confirmed in T47D-derived 2° mammo-
spheres by performing transwell migration assay under
conditions similar to those mentioned above (Figure 7H).
Taken together, these results establish that curcumin abro-
gates migration of bCSCs through perturbation of β-
catenin/Slug pathway and restoration of E-cadherin.
We next validated our in vitro results in bCSCs of
primary breast tumor samples. For this purpose, we
purified bCSCs flow-cytometrically from primary breast
tumors on the basis of the cell surface phenotype CD44
+/CD24−/low (Figure 8A) and confirmed their stemness
properties on the basis of the expression levels of the
following markers: MRP1 and ABCG2 (Figure 8B),
ALDH1 (Figure 8C), and Oct-4, Sox-2, and Nanog
(Figure 8D). These primary tumor-derived bCSCs were
next treated with curcumin for further validation of our
above-mentioned in vitro findings. In fact, supporting
our in vitro data, curcumin treatment rendered an
increase in E-cadherin protein expression along with a
concurrent decrease in the expression level of Slug in
breast tumor bCSCs, although no significant change
in the expression of β-catenin protein was observed
(Figure 8E).
Our findings altogether establish a novel role of curcu-
min in abrogating bCSC migration by restoring the
expression of the EMT suppressor E-cadherin, which is
normally suppressed in these highly migratory cells, via
amplification of E-cadherin/β-catenin negative feedback
loop.Discussion
In the present study, we have disclosed the inhibiting ef-
fect of the phytochemical curcumin on migration property
of bCSCs. Curcumin is reportedly a potent anti-cancer
agent which exerts its anti-cancer effects in multiple ways,
including negative regulation of cancer metastasis, angio-
genesis, apoptosis, cell-cycle progression, inflammation,
and multi-drug resistance [24,25,38,39]. In addition, cur-
cumin can target resistant CSCs by inducing apoptosis
[40]. In this study, we assessed the highly aggravated mi-
gration potential of bCSCs as compared with the non-
stem tumor cells, which comprise the vast majority of the
tumor. Aggressiveness of CSCs may justify the gradual
increase in the CSC content of the primary tumor with
increasing aggressiveness. Interestingly, curcumin retarded
the migration potential of the bCSCs by restoring the
expression of the inherently repressed EMT-suppressor,
E-cadherin. An in-depth study revealed that the curcumin
effect was materialized by the downregulation of nuclear
β-catenin expression, which in turn negatively affected its
pro-migratory transcriptional role, resulting in the dimin-
ished expression of its target gene Slug, a transcriptional
repressor of E-cadherin. From another view point, cur-
cumin treatment rendered greater E-cadherin/β-catenin
complex formation which further perturbed the nuclear
import of β-catenin. Thus, our work elucidates a thus-
far-unknown novel role of curcumin in targeting the
aggravated migration property of bCSCs by amplifying the
E-cadherin/β-catenin negative feedback loop.
According to the recent studies, CSCs not only are
tumor initiators but also are culprits of tumor metastasis
[41]. Importantly, these CSCs are largely evasive of the
currently existing cancer treatment modalities [42]. This
major drawback of existing treatment strategies has led
to the growth of considerable interest in alternative
treatments using natural remedies since they are more
tolerated and cause no significant toxicity as compared
with the side effects of chemotherapeutic treatments.
Curcumin, the Indian spice derived from the rhizomes
Figure 7 Curcumin retards activation of β-catenin/Slug pathway in breast cancer stem cells, thereby restoring E-cadherin. (A)
β-catenin-associated E-cadherin was assayed by co-immunoprecipitation from cell lysates of MCF-7-derived 2° mammospheres with or without
curcumin treatment using specific antibodies (left panel) or with normal human immunoglobulin G (IgG) as a negative control (right panel). To
ensure comparable protein loading, 20% of supernatant from immunoprecipitation (IP) sample was subjected to determination of α-actin by
Western blotting. (B) Western blotting was conducted to study the levels of total β-catenin and nuclear β-catenin in 2° mammospheres in
presence or absence of curcumin exposure. (C) The relative nuclear expression of β-catenin in 2° mammospheres with or without curcumin
treatment was visualized by immunofluorescence. (D, E) Under similar conditions, Western blotting was performed to study the expression levels
of β-catenin target genes Cyclin-D1, c-Myc, Slug, Snail, Vimentin, MMP-2 and MMP-9 in curcumin treated/untreated 2° mammospheres. (F) Protein
expression of E-cadherin in 2° mammospheres with or without curcumin or Slug-cDNA (or both) were determined by Western blotting (left
panel). The efficiency of transfection was determined by Western blot analysis (right panel). (G) Graphical quantifications of cell adhesion,
spreading, three-dimensional (3D) invasion, and migration assays of MCF-7-derived 2° mammospheres with or without curcumin and Slug-cDNA
treatment/transfection. (H) Transwell migration assay was performed under similar experimental conditions in T47D-derived 2° mammospheres.
α-Actin/histone H1/glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal loading control. Data are presented as
mean ± standard error of mean or representative of three independent experiments. Cont, control; Cur, curcumin.
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Figure 8 In vitro validation of the effects of curcumin on primary tumor-derived breast cancer stem cells (bCSCs). (A) Representative
flow cytometric cell-sorting data performed for the purification of bCSCs (CD44+/CD24−/low) from patient-derived primary breast tumor samples.
(B-D) Graphical representation of relative mean fluorescence intensities (MFIs) in arbitrary units (AU) of drug-resistance markers ABCG2 and MRP1,
stemness related enzyme ALDH1, and de-differentiation markers Oct-4, Sox-2, and Nanog in bCSCs and non-stem cancer cells (NSCCs) purified
from primary breast tumors, as determined by flow cytometry (right panels). Left panels depict representative flow cytometric histogram overlay
data. (E) Graphical representation of relative MFIs of E-cadherin, β-catenin and Slug in the bCSC population of primary tumor samples with or without
curcumin treatment as determined by flow cytometry (lower panels). Upper panels depict representative flow cytometric histogramoverlay data. Data are
presented as mean ± standard error of mean or representative of three independent experiments. Cont, control; CSC, cancer stem cell; Cur, curcumin.
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ied as a cancer chemopreventive agent in a wide range
of cancer models [38,39,43]. A plethora of molecular
targets and signaling pathways have been shown to be
modulated by curcumin, resulting in inhibition of can-
cer cell proliferation, invasion, metastasis, angiogenesis,
and induction of apoptosis [38,39]. In recent years,curcumin has also been reported to exert its anti-cancer
effects on CSCs [40]. A very recent report demonstrated
that curcumin targets breast cancer stem-like cells with
micro-tentacles that persist in mammospheres and pro-
mote reattachment [44]. However, there are no detail
studies on the anti-migratory effects of curcumin on
CSCs.
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associated mortality, thereby justifying the clinical need to
prevent or target metastasis [45,46]. It is known that EMT
is an essential developmental process that enables re-
programming of polarized epithelial cells toward a mesen-
chymal motile phenotype [47]. In normal adult tissues, the
typically dormant EMT program is reactivated during
wound repair and tissue regeneration. In contrast, the
non-metastatic cancer cells may undergo the EMT pro-
gram to attain the migratory and invasive potential
required for metastatic progression [48]. Recently, gene
expression patterns in human cancers have indicated that
de-differentiated cancer cells combine EMT properties
with a stem-cell like phenotype [11,49]. A direct molecular
link between EMT and stemness was demonstrated by the
observations that EMT activators, such as transforming
growth factor-beta 1 (TGFβ1), can co-induce EMT and
stemness properties, thereby linking the EMT and CSC
concept [50]. Cancer cells that undergo EMT lose epithe-
lial polarity and acquire invasive properties and stem cell-
like features, which are believed to prelude metastasis
[51]. This correlation between EMT and CSCs suggests
that the treatment strategies which target EMT regimen
may virtually restrain both CSCs and metastatic potential
of the tumor. In our present study, we report a novel func-
tion of curcumin in disrupting this complex ‘EMT-ambi-
ence’ of bCSCs which is also responsible for their
aggravated migratory property. Therefore, our results are
in keeping with a recent concept suggesting that CSCs
have characteristics of post-EMT cancer cells and that
these features further aid these CSCs for successful meta-
static colonization [41]. Targeting this transition (EMT)
among CSCs by curcumin therefore opens a new arena
for the treatment of highly malignant breast cancers.
Loss of E-cadherin-mediated cell adhesion is one of
the key mechanisms involved in metastatic conversion
of epithelial cells and EMT [52]. Numerous studies have
described a partial or complete loss of E-cadherin during
cancer progression, which is often correlated with an
unfavorable prognosis [53], confirming E-cadherin to be
a caretaker of the epithelial state. One of the probable
mechanisms involved in E-cadherin dysfunction, espe-
cially loss of its expression and consequent promotion of
tumor progression, is through β-catenin signaling [54].
As the main binding partner of β-catenin, E-cadherin
plays a pivotal role in β-catenin stabilization and func-
tion. Their functional complex formation is necessary
for adhesion and the maintenance of epithelial cell layers.
The loss of E-cadherin results in nuclear localization of
endogenous β-catenin [55]. On the other hand, E-
cadherin could potentially antagonize signaling activity of
β-catenin by sequestering β-catenin at the membrane,
thus keeping it away from the nucleus, as well as by com-
peting with LEF-1 for the same binding sites on β-catenin.If E-cadherin fails to associate with β-catenin, E-cadherin
is retained in the endoplasmic reticulum, where it is sub-
sequently degraded [56]. A functional cadherin-catenin
complex is therefore important for maintaining cellular
integrity [57]. In fact, increased concentration of free β-
catenin in the cytoplasm promotes its binding to the LEF/
TCF family of DNA-binding proteins. As a result, β-
catenin translocates to the nucleus, where it transcrip-
tionally activates specific target genes [12]. Accumulating
evidence suggests that several transcription factors, in-
cluding Slug and Snail, both of which are transcriptional
targets of β-catenin, are implicated in E-cadherin repres-
sion and EMT [12]. However, the expression of Snail is
suppressed in estrogen receptor-positive (ER+) breast can-
cer cell lines like MCF-7 and T47D [58], whereas Slug has
been proposed to be a likely in vivo repressor of E-
cadherin as compared with Snail in breast carcinomas
[59]. A report from Hajra et al. [59] further demonstrated
that, in breast cancer cell lines, Slug expression correlates
more strongly than snail expression with E-cadherin sup-
pression [59]. In keeping with these reports, our results
also revealed low expression of Snail in the ER+ breast
cancer cell line, MCF-7, while Slug played the key role in
maintaining the aggravated migration potential of bCSCs.
In breast cancer, curcumin has also been shown to re-
press expression of Slug [60]. More recently, a report on
MCF-7 cells showed that the effect of curcumin on bCSCs
is mediated through the inhibition of the self-renewal
property of these cells by exerting potent inhibition on
Wnt/β-catenin signaling [33]. Here, we report the yet-
unexplored anti-migratory effect of curcumin on bCSCs
by restoration of E-cadherin expression, which is mediated
through the negative regulation of the β-catenin/Slug path-
way. In fact, curcumin restores the E-cadherin/β-catenin
complex formation, which further impedes nuclear trans-
port of β-catenin that in turn increases E-cadherin ex-
pression through inhibition of Slug, thereby accentuating
the E-cadherin/β-catenin negative feedback loop. Cumula-
tively, curcumin targets bCSC migration by suppressing
their EMT phenotype, which in general imparts higher
migration potential to tumor cells.Conclusions
We demonstrate for the first time, to the best of our know-
ledge, that the phytochemical curcumin inhibits the aggra-
vated migration potential of bCSCs by perturbing
commencement of EMT. This could be a very promising
addition to traditional cancer treatments, including chemo-
therapy and radiotherapy, especially given the fact that
most chemotherapeutic drugs and radiotherapy do not
have the capability to eliminate CSCs. This combination
strategy will open a new avenue for more effective therap-
ies for highly invasive breast carcinomas.
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Additional file 1: Figure S1. (A and B) Effects of dose-dependent
treatment of curcumin on the percent cell viability of 2° spheres derived
from MCF-7 and T47D cells. Data are presented as mean ± SEM or
representative of three independent experiments. **p < 0.01.
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